HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A controlled trial of cyclophosphamide and azathioprine in Nigerian children with the nephrotic syndrome and poorly selective proteinuria.

Abstract
In a controlled trial, symptomatic treatment alone, or 12 weeks of cyclophosphamide or azathioprine were compared in Nigerian children with nephrotic syndrome (mainly quartan malarial nephropathy) and poorly selective proteinuria. Full remission in 2 patients in each of the two groups treated with drugs, and diminution of proteinuria in most patients in the cyclophosphamide group showed possible evidence of benefit. Infections during treatment were significantly more common in the drug-treated groups but were controllable. Mortality from renal failure in the 2nd year after treatment was significantly greater in the azathioprine-treated group than in the other two, suggesting that the drug may have exacerbated the nephritis. The 5-year survival rate was similar in the cyclophosphamide and the control group.
AuthorsA Adeniyi, R G Hendrickse, J F Soothill
JournalArchives of disease in childhood (Arch Dis Child) Vol. 54 Issue 3 Pg. 204-7 (Mar 1979) ISSN: 1468-2044 [Electronic] England
PMID373645 (Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article)
Chemical References
  • Cyclophosphamide
  • Azathioprine
Topics
  • Azathioprine (adverse effects, therapeutic use)
  • Child
  • Child, Preschool
  • Clinical Trials as Topic
  • Cyclophosphamide (adverse effects, therapeutic use)
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Nephrotic Syndrome (complications, drug therapy, mortality)
  • Nigeria
  • Proteinuria (drug therapy, etiology)
  • Random Allocation

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: